Innovative Discovery Could Revolutionize Kidney Transplant Rejection Diagnostics: Collaboration for Translation to Clinic
September 16, 2025
For over three decades, Dr. Manikkam Suthanthiran has been dedicated to one goal: making transplanted organs work better and longer in more patients. In 2001, his laboratory discovered that biological evidence of kidney transplant rejection can be detected in urine—a finding that culminated in a patented urine gene expression biomarker test that has been licensed to a biotech company for further commercialization. This noninvasive technology has the potential to predict kidney transplant rejection so that clinicians can intervene early and individualize treatments for patients.
Exploring Human Voice as a Biomarker
September 16, 2025
The human voice is unique for each individual and contains lots of acoustic data. A friend can tell something is not right if your voice sounds a little off. Voice is also widely used to verify a person’s identity. Do you know the frequency, speed of voice and even the way a person coughs can offer clues to health? Clinicians and researchers at Weill Cornell Medicine and their collaborators hope to harness the voice data to detect signs of diseases and train AI algorithm to improve the accuracy of diagnoses and predict disease progression.
From Academic Scientist to Biotech Executive: Dr. Vishwas Seshadri Inspires ABI Participants with His Career Story
September 10, 2025
The Fall 2025 Accelerating BioVenture Innovation (ABI) course officially kicked off on Sept. 2 in Uris Auditorium with guest speaker Dr. Vishwas Seshadri, chief executive officer of Abeona Therapeutics, Inc. In a wide-ranging interview with BioVenture eLab Director Loren Busby, Dr. Seshadri, a scientist turned biotech executive, spoke about R&D, manufacturing, leadership, regulatory affairs and market access.
NIH Grant Funds Effort to Target the Root of HIV Persistence
August 15, 2025
A multi-institutional team led by Weill Cornell Medicine has received a five-year, $14.9 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to find ways to remove latent HIV from the cells of individuals with HIV. The team aims to use a personalized medicine approach to transform the management of HIV into effective cures.
Pitch Competition Showcases How Artificial Intelligence, Big Data May Benefit Patients
July 10, 2025
BioVenture eLab’s Biomedical Innovation Challenge program celebrated its seventh cohort on June 24 with a final pitch event and scientific presentations in Uris Auditorium. This year’s competitors showcased artificial intelligence-enabled solutions aimed at improving early disease detection and enhancing health outcomes at scale.
New Insights into Bladder Cancer Treatment Could Help Improve Immunotherapies
May 29, 2025
A team of researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center (MSK) is expanding the understanding of how Bacillus Calmette-Guérin (BCG) works as a treatment of bladder cancer— an understanding that could help improve the effectiveness of immunotherapies more broadly.
Expanded Funding Program Strengthens Enterprise Innovation’s Ability to Nurture Promising Early-Stage Research
May 21, 2025
To support the continued diversification of Weill Cornell Medicine’s technology portfolio, Enterprise Innovation has created an overarching gap funding superstructure to advance innovation and commercialization opportunities.Making a Real-World Impact with Tangible Research Materials Commercialization
May 16, 2025
Tangible materials developed by Weill Cornell Medicine investigators are valuable assets to both the research community and biomedical industry. By commercializing such materials, investigators can propel translational science as well as create revenue for their labs. Dr. Lukas Dow, a professor of biochemistry in medicine who has a decade of experience in commercializing tangible materials, shared his insights with Enterprise Innovation.
AI Tool Accurately Sorts Cancer Patients by their Likely Outcomes
May 12, 2025
A new artificial intelligence-based method accurately sorts cancer patients into groups that have similar characteristics before treatment and similar outcomes after treatment, according to a study led by investigators at Weill Cornell Medicine. The new approach has the potential to enable better patient selection in clinical trials and better treatment selection for individual patients.
The Power of Partnership in Innovation
April 14, 2025
Nearly 200 scientists, investors and industry representatives attended Weill Cornell Medicine’s 2025 Biomedical Innovation Conference (“BioInnovate”) April 1, sharing their startup journeys and experiences nurturing biomedical advances into health care products and companies.